Samsung Bioepis receives closing European acclaim for its Remicade copy

employees stroll commonly workplace constructing of Samsung Electronics in Seoul, South Korea, in this file image taken on January 6, 2016. Reuters/Kim Hong-Ji

South Korea's Samsung Bioepis talked about on Monday its biosimilar of Johnson & Johnson's (JNJ.N) blockbuster rheumatoid arthritis drug Remicade has obtained ultimate approval from European regulators, paving the style for its second product launch in Europe.

Samsung Bioepis, an unlisted arm of South Korea's exact conglomerate Samsung community [SAGR.UL], also said final week the biosimilar had been submitted for evaluate within the united states.

A relative latecomer to the business, Samsung Bioepis has discovered early success by way of beating rivals to market on one of the crucial world's good-promoting medicine. It grew to be the first business to launch a biosimilar version of Amgen's (AMGN.O) Enbrel, an additional rheumatoid arthritis drug, in Europe.

Samsung Biologics, Bioepis' mother or father company, is planning an preliminary public providing in South Korea by the conclusion of the 12 months that analysts say may carry up to 3 trillion received ($2.5 billion).

Samsung Bioepis observed minority shareholder and companion Biogen (BIIB.O) might be liable for the commercialization and distribution of its Remicade reproduction, referred to as Flixabi in Europe.

Biosimilars, lower-cost copies of complicated biotech drugs, are nevertheless particularly new but interest is turning out to be right away as establishments such as Bioepis launch more cost-effective models of blockbuster medication.

The Samsung community hopes the biosimilars business will grow to be a brand new growth driver as world demand for smartphones plateaus, weighing on the outlook for its flagship company Samsung Electronics (005930.KS).

($1 = 1,190.0000 gained)

(This version of the story corrects paragraph 2 to claim Bioepis' announcement of U.S. submission became final week, no longer the submission itself)

(Reporting by way of Se young Lee; modifying by using Edwina Gibbs)